Brainomix has expanded a partnership with drugmaker Boehringer Ingelheim to advance clinical use of the e-Lung AI imaging platform for early detection of progressive pulmonary fibrosis (PPF).
The e-Lung AI platform has been clinically validated to measure lung features associated with interstitial lung diseases (ILD), precursors of PPF, according to Brainomix. The next phase of the collaboration will center on PROGRESS-PPF, a prospective multicenter study in the U.S. to evaluate whether routine use of e-Lung can support earlier clinical diagnosis of PPF, the company said.
The expansion follows results from the REVISE-PPF retrospective study with the University of Chicago, Weill Cornell Medical Center, and the University of Alabama at Birmingham. This study found that e-Lung identified patients with radiologic evidence of PPF up to 28 months earlier than local clinical diagnoses, Brainomix noted.
e-Lung is a U.S. Food and Drug Administration (FDA)-cleared, AI-driven platform that automatically detects and quantifies abnormalities on thoracic CT scans, including subtle deterioration across multiple timepoints. Results from the retrospective study will be presented at the American Thoracic Society International Conference in Orlando, FL, on May 17, the company said.
